Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sodium oligomannate
- Development stage
- Phase 4
- Lead developer
- Green Valley Group
- Modality
- Microbiome-Derived Products → Microbiome Therapeutics, Small Molecules
- Administration
- Oral
01
Overview
Sodium oligomannate is a mixture of linear, acidic oligosaccharides derived from the marine algae Ecklonia kurome. It is used in China for the treatment of mild to moderate Alzheimer's disease to improve cognitive function. The drug was conditionally approved in China in 2019 but has not been approved elsewhere due to insufficient clinical data. Its mechanism of action is not fully understood, but proposed mechanisms include inhibition and destabilization of amyloid beta aggregation, modulation of gut microbiota leading to reduced neuroinflammation, and prevention of inflammatory responses associated with amyloid plaques. Sodium oligomannate modestly penetrates the blood-brain barrier and may act through multiple pathways related to both amyloid pathology and inflammation[1][3][7][8].
- Brand names
- OligomannateHamput SodiumMannut SodiumNine Phase One
- Other names
- sodium oligo-mannurarate
02
Targets
Aβ (Amyloid-beta peptides and aggregates)
Beyond the preview
Go deeper on sodium oligomannate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sodium oligomannate.